Searched for
CONCORD BIOTECH USFDA NOD
Ben Lamm and Colossal Biosciences: The billionaire tech founder behind the $10 billion plan to bring back extinct animalsTech entrepreneur Ben Lamm is spearheading Colossal Biosciences, a company aiming to bring back extinct species like the woolly mammoth thr...- US stocks: S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on IranUS market saw a mixed close as the S&P 500 and Nasdaq dipped, primarily due to tech giants like Alphabet facing investor scrutiny over AI s...
- When frontier AI can be switched off: India's sovereignty challengeIndia must not depend on foreign AI models, as US export controls demonstrate potential access denial. Past reliance on external tech, like...
- Micron Technology stock price jumps on Monday, shares up nearly 300 per cent for 2026U.S. Stock Market today: Micron Technology shares moved higher in premarket trading on Monday. AI-driven optimism has supported Wall Stree...
- Central Drugs Laboratories find 46 drug samples not of standard quality for MayHealth officials revealed that in May 2026, 46 drug samples tested by Central Drugs Laboratories and 113 by State Drugs Testing Laboratorie...
- ArcelorMittal partners with AWS to automate global operationsSteel giant ArcelorMittal is joining forces with Amazon Web Services (AWS) to revolutionize its global operations. By integrating AWS's clo...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
- Sell or Hold: Citi maintains buy on Cipla; Motilal Oswal recommends buy on RIL post AGMBrokerages remain bullish on Cipla and Reliance Industries, citing strong growth drivers and attractive valuations. Citi highlights regulat...
- Russia eyes ports, biotech for rupee surplus investments in IndiaRussia is eyeing India's burgeoning infrastructure, particularly its ports, for investments using accumulated rupee funds. Discussions are ...
- India bans 16 fixed-dose drug combinations over safety concernsIn a significant public health initiative, the ban on 16 fixed-dose drug combinations, including various antibiotics and topical formulatio...
- SBI Funds Management gets Sebi nod for IPOSBI Funds Management, India's largest mutual fund house, has secured SEBI's nod for its upcoming Initial Public Offering, expected to launc...
- Rs 19,700-crore carbon capture scheme gets nodThe carbon capture, utilisation and storage (CCUS) scheme is expected to attract investments of about ₹37,500 crore and create carbon-captu...
- Alembic Pharma gets tentative nod from USFDA for generic cancer drugAlembic Pharmaceuticals has secured tentative approval from the USFDA for its generic Binimetinib tablets. This marks a significant step fo...
- USFDA concludes inspection at Jubilant HollisterStier's Spokane plant with 8 observationsJubilant Pharmova announced its US subsidiary, Jubilant HollisterStier LLC, underwent a USFDA inspection. The facility in Spokane, Washingt...
- Aurobindo Pharma clears key US hurdle in Lannett acquisition, closing expected soonIndian drug giant Aurobindo Pharma is set for a major US expansion. The company has received crucial antitrust clearance from the US Federa...
- Mutual funds added these 4 new stocks to their portfolios in May. Check detailsMutual funds introduced four new stocks into their portfolios in May, according to Prime Database disclosures. Afcom Holdings saw the highe...
- Karnataka explores biotech financing framework, AI-led innovation to support sector growthKarnataka is developing a dedicated support framework for its biotechnology sector, encompassing funding, mentoring, and regulatory guidanc...
- Two Trades for Today: A maker of forged components for a 7.7% gain, a mid-cap pharma stock for a 6% upmoveOur technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...
- Concord Biotech shares gain 6% after USFDA approval for Tofacitinib tabletsConcord Biotech's shares surged over 6% after receiving USFDA approval for its Tofacitinib Tablets in 5 mg and 10 mg strengths. This approv...
- Concord Biotech shares jump 8% on USFDA nod for Mycophenolate Mofetil oral suspensionConcord Biotech shares saw a significant jump on Wednesday. This surge followed the company's announcement of receiving approval from the U...
Load More
